Swissmedic, the Swiss Agency for Therapeutic Products, approved Novartis AG’s (NYSE:NVS) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved ...
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback